Format

Send to

Choose Destination
J Gastroenterol. 2019 Aug;54(8):718-729. doi: 10.1007/s00535-019-01572-y. Epub 2019 Mar 27.

Systematic review with network meta-analysis: indirect comparison of the efficacy of vonoprazan and proton-pump inhibitors for maintenance treatment of gastroesophageal reflux disease.

Author information

1
Division of Gastroenterology, Department of Internal Medicine, Hyogo College of Medicine, 1-1 Mukogawa, Nishinomiya, Hyogo, 663-8501, Japan. miwahgi@hyo-med.ac.jp.
2
Department of Health Economics and Outcomes Research, Graduate School of Pharmaceutical Sciences, The University of Tokyo, Hongo 7-3-1, Bunkyo-ku, Tokyo, 113-0033, Japan.
3
Japan Medical Affairs, Takeda Pharmaceutical Company Ltd, 1-1, Nihonbashi-honcho 2-chome, Chuo-ku, Tokyo, 103-8668, Japan.
4
Japan Medical Affairs, Takeda Pharmaceutical Company Ltd, 1-1, Doshomachi 4-chome, Chuo-ku, Osaka, 541-0054, Japan.
5
Center for Medical Statistics, 2-9-6 Higashi Shimbashi, Minato-ku, Tokyo, 105-0021, Japan.

Abstract

BACKGROUND:

Long-term maintenance treatment of gastroesophageal reflux disease (GERD) is important to prevent relapse. Proton-pump inhibitors (PPIs) are used for both treatment and maintenance therapy of GERD. Recently, a potassium-competitive acid blocker vonoprazan was launched in Japan. We evaluated the comparative efficacy of vonoprazan and other PPIs for GERD maintenance.

METHODS:

A systematic literature search was performed using MEDLINE and Cochrane Central Register of Controlled Trials. Double-blind randomized controlled trials (RCTs) of PPIs, vonoprazan, and placebo for GERD maintenance published in English or Japanese were selected. Among them, studies conducted at the recommended dose and for the recommended use, and containing information on maintenance rate based on endoscopic assessment, were included. The comparative efficacies of treatments were estimated by performing a Bayesian network meta-analysis, which assessed the consistency assumption. Outcomes were number or rate of patients who maintained remission.

RESULTS:

Of 4001 articles identified, 22 RCTs were eligible for analysis. One study published as an abstract was hand-searched and added. The consistency hypothesis was not rejected for the analysis. The odds ratio of vonoprazan 10 mg to each PPI was 13.92 (95% credible interval [CI] 1.70-114.21) to esomeprazole 10 mg; 5.75 (95% CI 0.59-51.57) to rabeprazole 10 mg; 3.74 (95% CI 0.70-19.99) to lansoprazole 15 mg; and 9.23 (95% CI 1.17-68.72) to omeprazole 10 mg.

CONCLUSIONS:

The efficacy of vonoprazan in GERD maintenance treatment may be higher than that of some PPIs. However, a direct comparison of vonoprazan and PPIs is required to confirm these effects.

KEYWORDS:

Gastroesophageal reflux disease; Network meta-analysis; Potassium-competitive acid blocker; Proton-pump inhibitor; Vonoprazan

Supplemental Content

Full text links

Icon for Springer Icon for PubMed Central
Loading ...
Support Center